James Misselbrook, Ph.D.
Founder & CEO
Established and led oligonucleotide capabilities from RUO to GMP scale at Agilent, Synthego and Curative, with deep expertise in platform development, commercial scale-up and product launches across RNA and oligonucleotide therapeutics.
